In response to suggestions from non-proliferation advocates that highly enriched uranium (HEU) used in the production of medical isotopes should be eliminated due to security concerns, the U.S. Department of Energy and National Nuclear Security Administration have developed the “Global Threat Reduction Initiative.” As part of this initiative, the following goals have been established:
The nuclear medicine industry supports this transition. Through the Council on Radionuclides and Radiopharmaceuticals, the industry continues to work with CMS, DOE and the U.S. Food and Drug Administration to examine methods to “pull” more non-HEU based Mo-99 into the United States.
Currently the two U.S. manufacturers of Mo99 generators are in the midst of a complex period of transition between HEU and non-HEU molybdenum production. Full conversion to non-HEU reactor sources is expected to be complete in or around 2017. In addition, a number of new technologies are in development, with support of U.S. Government grants, with the goal of developing non-HEU alternatives to traditional production processes.
Non-HEU derived radiopharmaceuticals are available for order through your Triad Isotopes pharmacy. Please note that, until reactor conversion is complete, the following limitations may apply: